Unicycive Therapeutics Inc (UNCY)
Official siteHEALTHCARE • BIOTECHNOLOGY • NASDAQ
Market Cap: $97.25M
Last updated: Nov 17, 2026 at 4:43 PM ET
Unicycive Therapeutics Inc (UNCY) Statistics
Unicycive Therapeutics (UNCY) has a market cap of $97.25M and an enterprise value of $55.28M. Its share count is up 56.49% from a year earlier. Revenue fell 100.00% over the last 12 months from the 12 months before.
Total Valuation
Enterprise value is 43.15% below the market cap, as cash exceeds debt.
| Market Cap | $97.25M |
|---|---|
| Enterprise Value | $55.28M |
| Latest price (Nov 17, 2026) | $3.70 |
Key Dates
The next earnings report is expected on Mar 29, 2027, covering the quarter ending Dec 31, 2026.
| Next Earnings Date | Mar 29, 2027 (expected) |
|---|---|
| Last Earnings Date | Nov 16, 2026 |
| Fiscal Year End | December |
Valuation Ratios
| Forward P/S | 71.0x |
|---|---|
| P/B Ratio | 2.0x |
Price Statistics
The stock is down 34.74% over 52 weeks and trades 10.63% below its 50-day average.
| Beta (1Y) | 1.11 |
|---|---|
| 52-Week Change | -34.74% |
| 1-Month Change | +5.41% |
| 3-Month Change | -33.69% |
| 6-Month Change | -52.13% |
| 5-Year Change | -87.06% |
| Total Return (1Y) | -34.74% |
| Total Return (3Y CAGR) | -9.71% |
| Total Return (5Y CAGR) | -32.05% |
| Return vs SPY (1Y) | -49.06% |
| Max Drawdown (1Y) | -60.75% |
| Max Drawdown (3Y) | -86.82% |
| Sharpe Ratio (1Y) | -0.56 |
| Correlation with SPY (1Y) | 0.18 |
| 50-Day Average | $4.14 |
| 200-Day Average | $5.92 |
| 52-Week Range | $3.33 to $8.74 |
| RSI (14 Days) | 46.6 |
| Average Volume (20 Days) | 1.06M |
The 5-year change compares month-end closes, adjusted for splits, through Oct 2026.
Financial Position
Current assets cover 4.00x current liabilities, and total debt is 0.00x shareholder equity.
| Current Ratio | 4.00x |
|---|---|
| Quick Ratio | 4.00x |
| Debt / Equity | 0.00x |
Returns and Efficiency
Return on equity is -68.81% and return on assets is -51.78% over the last 12 months.
| Return on Equity (ROE) | -68.81% |
|---|---|
| Return on Assets (ROA) | -51.78% |
| ROIC (5Y Average) | -71.93% |
Scores
UNCY has a Piotroski F-Score of 2 of 9, in the weak band of 0 to 2.
Piotroski F-ScoreWeak at 2 or lessStrong at 8 or more
| Piotroski F-Score | 2 of 9 |
|---|---|
| Piotroski Strength | Weak |
Income Statement
Revenue was $0 over the last 12 months.
| Revenue | $0 |
|---|---|
| Revenue Growth (YoY) | -100.00% |
| Gross Profit | -$151.00K |
| Operating Income | -$34.64M |
| Pretax Income | -$36.21M |
| Net Income | -$36.21M |
| Reported EPS (TTM) | -$1.67 |
Trailing 12 months through Sep 30, 2026.
Balance Sheet
Shareholder equity funds 75.25% of the $69.93M in total assets.
| Cash and Equivalents | $41.97M |
|---|---|
| Total Debt | $0 |
| Net Cash | $41.97M |
| Net Cash Per Share | $1.48 |
| Working Capital | $51.85M |
| Shareholder Equity | $52.62M |
| Book Value Per Share | $1.86 |
| Total Assets | $69.93M |
| Total Liabilities | $17.31M |
Balance sheet as of Sep 30, 2026.
Cash Flow
After $230.00K of capital spending, operating cash flow left -$29.36M of free cash flow.
| Operating Cash Flow | -$29.13M |
|---|---|
| Capital Expenditures | $230.00K |
| Free Cash Flow | -$29.36M |
| FCF Per Share | -$1.07 |
| Depreciation and Amortization | $587.00K |
Trailing 12 months through Sep 30, 2026.
Dividends and Yields
UNCY does not pay a dividend. Its free cash flow yield is -28.06%.
| FCF Yield | -28.06% |
|---|---|
| Shareholder Yield | 0.00% |
Stock Splits
The last split was a 1-for-10 reverse split on Jun 20, 2025.
| Last Split Date | Jun 20, 2025 |
|---|---|
| Split Type | Reverse split |
| Split Ratio | 1:10 |
Price Target
Analyst price targets are part of paid GNG plans. See plans
Frequently Asked Questions About UNCY
What is UNCY's market cap?
Unicycive Therapeutics has a market cap of $97.25M. Its enterprise value, which adds debt and subtracts cash, is $55.28M.
How many shares of UNCY are outstanding?
Unicycive Therapeutics has 28.27M shares outstanding. The count is up 56.49% from a year earlier.
Does UNCY pay a dividend?
No. Unicycive Therapeutics does not pay a dividend.
How much debt does UNCY have?
Unicycive Therapeutics has $0 of total debt and $41.97M of cash and equivalents, a net cash position of $41.97M.
UNCY pages: Overview, Charting, Earnings, Forecast, Financials, Statistics, Competitors